0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia - Epidemiology Forecast to 2028
Published Date: April 2019
|
Report Code: DELV-Epid-345
Home | Market Reports | Health | Health Conditions | Heart & Hypertension
Familial Hypercholesterolemia Epidemiology Forecast to 2028

Familial Hypercholesterolemia (Type II Hyperlipoproteinemia - Epidemiology Forecast to 2028

Code: DELV-Epid-345
Report
April 2019
50 Pages
Delveinsight
Region: Global,
Description
Table of Content
Tables & Figures

DelveInsight's "Familial Hypercholesterolemia (Type II Hyperlipoproteinemia - Epidemiology Forecast, 2028” report provides a comprehensive analysis of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2028

Familial Hypercholesterolemia (Type II Hyperlipoproteinemia Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia outlook. It also includes the explanation of changing trends of epidemiology outlining the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia scenario.

Familial Hypercholesterolemia (Type II Hyperlipoproteinemia Epidemiology Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope
• The report covers detailed overview of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Familial Hypercholesterolemia (Type II Hyperlipoproteinemia Report assesses the disease risk and burden and highlights the unmet needs
• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths
• 10 Year Forecast
• 7MM Coverage
• Total Cases in Familial Hypercholesterolemia (Type II Hyperlipoproteinemia

Key assessments
• Patient Segmentation in Familial Hypercholesterolemia (Type II Hyperlipoproteinemia
• Familial Hypercholesterolemia (Type II Hyperlipoproteinemia Risk & Burden
• Factors driving growth in a specific Familial Hypercholesterolemia (Type II Hyperlipoproteinemia patient population

1. Report Introduction
2. Familial Hypercholesterolemia (Type II Hyperlipoproteinemia Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in 2016
2.2. Patient Share Distribution of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in 2028
3. Disease Background and Overview: Familial Hypercholesterolemia (Type II Hyperlipoproteinemia
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in 7MM
4.3. Total Prevalent/ Incident Patient Population of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in 7MM – By Countries
5. Epidemiology of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia
5.1.3. Sub-Type Specific cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia *
5.1.4. Sex- Specific Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia *
5.1.5. Diagnosed Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia
5.4.3. Sub-Type Specific cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia *
5.4.4. Sex- Specific Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia *
5.4.5. Diagnosed Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia
5.5.3. Sub-Type Specific cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia *
5.5.4. Sex- Specific Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia *
5.5.5. Diagnosed Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia
5.6.3. Sub-Type Specific cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia *
5.6.4. Sex- Specific Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia *
5.6.5. Diagnosed Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia
5.7.3. Sub-Type Specific cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia *
5.7.4. Sex- Specific Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia *
5.7.5. Diagnosed Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia
5.8.3. Sub-Type Specific cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia *
5.8.4. Sex- Specific Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia *
5.8.5. Diagnosed Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia
5.9.3. Sub-Type Specific cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia *
5.9.4. Sex- Specific Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia *
5.9.5. Diagnosed Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia
6. Unmet Needs of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific

List of Tables :

Table 1: Total Prevalent/Incident Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in 7MM
Table 2: Total Prevalent/Incident Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in United States (2016-2028)*
Table 5: Sex- Specific Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in United States (2016-2028)*
Table 6: Diagnosed Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in Germany (2016-2028) *
Table 9: Sex- Specific Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in Germany (2016-2028) *
Table 10: Diagnosed Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in France (2016-2028)
Table 12: Sub-Type Specific cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in France (2016-2028) *
Table 13: Sex- Specific Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in France (2016-2028) *
Table 14: Diagnosed Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in Italy (2016-2028) *
Table 17: Sex- Specific Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in Italy (2016-2028) *
Table 18: Diagnosed Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in Spain (2016-2028) *
Table 21: Sex- Specific Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in Spain (2016-2028) *
Table 22: Diagnosed Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in UK (2016-2028) *
Table 25: Sex- Specific Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in UK (2016-2028) *
Table 26: Diagnosed Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in Japan (2016-2028) *
Table 29: Sex- Specific Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in Japan (2016-2028) *
Table 30: Diagnosed Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in Japan (2016-2028)


LIst of Figures :

Figure 1: Total Prevalent/Incident Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in 7MM
Figure 2: Total Prevalent/Incident Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in United States (2016-2028)*
Figure 5: Sex- Specific Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in United States (2016-2028)*
Figure 6: Diagnosed Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in Germany (2016-2028) *
Figure 9: Sex- Specific Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in Germany (2016-2028) *
Figure 10: Diagnosed Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in France (2016-2028) *
Figure 13: Sex- Specific Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in France (2016-2028) *
Figure 14: Diagnosed Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in Italy (2016-2028) *
Figure 17: Sex- Specific Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in Italy (2016-2028) *
Figure 18: Diagnosed Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in Spain (2016-2028) *
Figure 21: Sex- Specific Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in Spain (2016-2028) *
Figure 22: Diagnosed Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in UK (2016-2028) *
Figure 25: Sex- Specific Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in UK (2016-2028) *
Figure 26: Diagnosed Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in Japan (2016-2028) *
Figure 29: Sex- Specific Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in Japan (2016-2028) *
Figure 30: Diagnosed Cases of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia in Japan (2016-2028)

SELECT A FORMAT
Added to Cart

Electronic (PDF)
$3250
This license allows only one user to access the PDF.

Electronic (PDF)
$6500
This license allows all the users of an enterprise residing in one location to access the PDF

Electronic (PDF)
$9750
This license allows all the employees of an enterprise to access the PDF.
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Nano String

RELATED REPORTS

Global and United States Pacemakers and Implantable Cardioverter Defibrillators Market Report Forecast 2022 2028
Global and United States Pacemakers and Implantable Cardioverter Defibrillators Market Report & Forecast 2022-2028

An implantable cardioverterdefibrillator is a specialized implantable electronic device designed to directly treat a cardiac tachyarrhythmia whereas a permanent pacemaker is an implanted device that provides electrical stimuli.Market Analysis and Insights Global and United States Pacemakers and Implantable Cardioverter Defibrillators MarketThis report focuses on global and United States Pacemakers and Implantable Cardioverter Defibrillators market also covers the segmentation data of other regions in regional level and county level.Due to the COVID19 pandemic the global Pacemakers and Implantable Cardioverter Defibrillators market size is estimated to be worth US million in 2022 and is forecast to a readjusted size of US million by 2028 with a CAGR of during the review period.

120 Pages
Type: Report
Code: QYRE-Auto-11P10580
Tue Jun 07 00:00:00 UTC 2022

Add to Cart

Global and United States Peripheral Vascular Surgical Devices Market Report Forecast 2022 2028
Global and United States Peripheral Vascular Surgical Devices Market Report & Forecast 2022-2028

Peripheral vascular surgical devices refer to special medical devices used in vascular surgery interventional cardiology interventional radiology and peripheral vascular procedures.Market Analysis and Insights Global and United States Peripheral Vascular Surgical Devices MarketThis report focuses on global and United States Peripheral Vascular Surgical Devices market also covers the segmentation data of other regions in regional level and county level.Due to the COVID19 pandemic the global Peripheral Vascular Surgical Devices market size is estimated to be worth US million in 2022 and is forecast to a readjusted size of US million by 2028 with a CAGR of during the review period.

120 Pages
Type: Report
Code: QYRE-Auto-8N10687
Tue Jun 07 00:00:00 UTC 2022

Add to Cart

Global and United States Coronary Stent Devices Market Report Forecast 2022 2028
Global and United States Coronary Stent Devices Market Report & Forecast 2022-2028

Coronary stents are tubelike expandable metallic devices which are introduced into coronary arteries that are clogged due to an underlying atherosclerosis disease.Market Analysis and Insights Global and United States Coronary Stent Devices MarketThis report focuses on global and United States Coronary Stent Devices market also covers the segmentation data of other regions in regional level and county level.Due to the COVID19 pandemic the global Coronary Stent Devices market size is estimated to be worth US million in 2022 and is forecast to a readjusted size of US million by 2028 with a CAGR of during the review period.

120 Pages
Type: Report
Code: QYRE-Auto-33O10296
Tue Jun 07 00:00:00 UTC 2022

Add to Cart

Global and United States Stroke Treatment Drugs Market Report Forecast 2022 2028
Global and United States Stroke Treatment Drugs Market Report & Forecast 2022-2028

Stroke is a disruption in brain function caused by lack of blood flow to the brain.Market Analysis and Insights Global and United States Stroke Treatment Drugs MarketThis report focuses on global and United States Stroke Treatment Drugs market also covers the segmentation data of other regions in regional level and county level.Due to the COVID19 pandemic the global Stroke Treatment Drugs market size is estimated to be worth US million in 2022 and is forecast to a readjusted size of US million by 2028 with a CAGR of during the review period.

120 Pages
Type: Report
Code: QYRE-Auto-27B10301
Tue Jun 07 00:00:00 UTC 2022

Add to Cart